Membranski glomerulonefritis - novosti u patogenezi i liječenju

Scientific paper - Review paper

• Title (english): Membranous glomerulonephritis - recent advances in pathogenesis and treatment
• Author: Ivica Horvatić
• Author: Krešimir Galešić
• Author's institution: University of Zagreb; School of Medicine
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences

Abstract (english)

Membranous glomerulonephritis is one of the leading causes of nephrotic syndrome in adults. It may have very variable course, with some patients slowly progressing to renal failure and some entering spontaneous remission. The aim of this article is to review recent advances in the pathogenesis and treatment of the disease in recent years. In recent years, first human podocyte autoantigens, responsible for autoantibodies and in situ immune complexes formation, were discovered: neutral endopeptidase, m-type phospholipase A2 receptor, superoxide-dismutase 2, aldose-reductase, alpha-enolase. It is postulated that these discoveries will help in differentiation between primary and secondary membranous glomerulonephritis, in predicting remission and/or relapse and also in determining more specific therapy. There have been also some pilot studies recently, in which new drugs have been introduced in the treatment of membranous glomerulonephritis: ACTH, rituximab and tacrolimus.

Abstract (croatian)

Membranski glomerulonefritis jedan je od najčešćih uzroka nefrotskog sindroma u odraslih osoba. Obilježen je varijabilnim kliničkim tijekom, u kojem se u nekih bolesnika sporo razvija zatajenje bubrega, dok drugi ulaze u spontanu remisiju. Cilj je ovoga preglednog članka osvrt na novosti koje su posljednjih godina nađene u patogenezi i liječenju ove bolesti u ljudi. Posljednjih godina otkriveni su ciljni podocitni autoantigeni koji su odgovorni za stvaranje autoprotutijela i imunih kompleksa in situ: neutralna endopeptidaza, M-tip receptora za fosfolipazu A2, superoksid-dismutaza 2, aldoza-reduktaza i a-enolaza. Pretpostavlja se da će otkrića ovih antigena pomoći u razlikovanju primarnog od sekundarnoga membranskoga glomerulonefritisa, predviđanju remisije i/ili relapsa bolesti, kao i specifičnijem liječenju bolesti. Posljednjih godina u liječenju bolesti provedene su pilot-studije u kojima su prvi put pokazani pozitivni terapijski učinci ACTH, rituksimaba i takrolimusa.

• Keywords (english): Glomerulonephritis, Membranous/physiopathology; Glomerulonephritis, Membranous/therapy; Humans
• Language: croatian
• Publication type: Scientific paper - Review paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Liječnički vjesnik
• Numbering: vol. 134, no. 11-12, pp. 328-339
• p-ISSN: 0024-3477
• URN:NBN: urn:nbn:hr:105:830096
• Publication: 2012-11
• Document URL: http://lijecnicki-vjesnik.hlz.hr/lijecnicki-vjesnik/membranski-glomerulonefritis-novosti-u-patogenezi-i-lijecenju/
• Type of resource: Text
• Access conditions: Open access
• Created on: 2024-03-27 20:04:24